The STRO-004 early clinical data is the primary catalyst, validating the platform and de-risking the pipeline. Traders should monitor for the next STRO-004 update in 1H 2027 and the initiation of the STRO-006 Phase 1 trial in Q3 2026. The cash runway into Q2 2028 removes near-term financing risk.
Drugs in focus
STRO drug pipeline →STRO-004
● Neutral Named in this 8-K- Impact
- Phase
- Phase 1
- Time to market
- Still in Phase 1 dose escalation; assuming successful Phase 1/2 and pivotal trials, potential approval would be several years away, likely 2029 or later.
- Next catalyst
- None dated
What to watchThe Phase 1 dose-escalation data from August 2026 showed early signals of activity (confirmed and unconfirmed partial responses) but also dose-limiting toxicities at the highest dose. The next update in H1 2027 will include expansion cohorts and more mature efficacy/safety data. Investors should watch for the dose selected for expansion, the durability of responses, and whether the safety profile supports a competitive advantage over the approved tissue-factor ADC Tivdak (tisotumab vedotin).
Price Chart
Executive Summary
Sutro Biopharma reported Q2 2026 revenue of $9.8M (vs $63.7M YoY) and a net loss of $38.5M (EPS -$2.33 vs -$1.35 YoY), a significant decline from the prior year which included a large milestone payment. However, the stock catalyst is the early Phase 1 data for STRO-004, showing confirmed and unconfirmed partial responses in heavily pretreated pancreatic, head and neck, and NSCLC patients with a favorable tolerability profile and differentiated PK. The clinical validation of the platform is the primary driver, outweighing the weak financial quarter for a clinical-stage biotech.
Key Financial Metrics
Key Facts
- Revenue was $9.8M for Q2 2026, down from $63.7M in Q2 2025, with the 2026 amount related principally to the Astellas collaboration.
- Net loss was $38.5M (EPS -$2.33) vs $11.5M (EPS -$1.35) in Q2 2025.
- Cash, cash equivalents and marketable securities were $164.3M as of June 30, 2026, expected to support operations into at least Q2 2028.
- STRO-004 Phase 1 data shows confirmed and ongoing unconfirmed partial responses in pancreatic, head and neck, and NSCLC at dose levels 3-4 mg/kg.
- Favorable tolerability profile with mostly low-grade AEs; discontinuation rate due to AEs was 6%.
- STRO-004 has a half-life of nearly seven days, preserving 98% DAR8 configuration with low free payload.
- STRO-006 on track to enter the clinic in Q3 2026; STRO-227 IND submission expected in 2026.
- Second Astellas dual-payload iADC program expected to enter the clinic in 2H 2026.
Financial Impact
Revenue declined $53.9M YoY due to the absence of a large milestone payment; net loss widened by $27.0M. Cash burn of ~$38.3M in Q2.
Risk Factors
- STRO-004 data is early (Phase 1 dose escalation, n=49) with limited follow-up; responses are not yet durable.
- Revenue is highly dependent on collaboration milestones, which are unpredictable.
- Significant stockholders' deficit of $103.3M and deferred royalty obligation of $239.1M.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-345733 |
| Document: stro-20260812.htm | 0001193125-26-345733 |
| Document: stro-ex99_2.htm | 0001193125-26-345733 |
| Document: 0001193125-26-345733-index-headers.html | 0001193125-26-345733 |
| Document: 0001193125-26-345733-index.html | 0001193125-26-345733 |
| Document: 0001193125-26-345733.txt | 0001193125-26-345733 |
| 8-K Data (Synthetic) | 0001193125-26-345733 |
Track record
8 reports on STRO
2 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +50.74% at T+20 after the Mar 23, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Bearish 5/10 Entry $9.82 to $9.32 Now $9.32 +5.09% ▲ +5.09% +3.18% vs SPY
- Nov 9, 20267d ago SC 13G Neutral 3/10 Entry $10.61 to $10.17 Now $9.32 −12.16% ▼ −4.15% −3.78% vs SPY
- Aug 12, 202613w ago 8-K Bullish 7/10 Viewing No price data
- Aug 12, 202613w ago Press Release Mixed 6/10 Entry $21.30 to $21.31 Now $9.32 −56.24% ▲ +0.05% −0.65% vs SPY
- Apr 22, 202629w ago DEFA14A Neutral 3/10 Entry $34.83 to $33.33 Now $9.32 −73.24% ▼ −4.31% −5.09% vs SPY
- Apr 19, 202630w ago Press Release Bullish 7/10 Entry $34.58 to $34.35 Now $9.32 −73.05% ▼ −0.67% −0.01% vs SPY
- Mar 23, 202634w ago S-3 Bearish 6/10 Entry $23.57 to $23.50 Now $9.32 +60.46% ▲ +0.30% +0.86% vs SPY
- Mar 23, 202634w ago Press Release Bullish 7/10 Entry $23.57 to $23.50 Now $9.32 −60.46% ▼ −0.30% −0.86% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers